Styles of communication University of Florida, Psychiatry Dept.

Slides:



Advertisements
Similar presentations
Drugs used in the Treatment of Alcohol Abuse/Addiction Tristan Knowles.
Advertisements

MEDICATION ASSISTED ADDICTION TREATMENT: APPROPRIATE USE DAS Quarterly Provider Meeting Louis E. Baxter, Sr., M.D., FASAM Medical Director-DAS President.
2008 Johns Hopkins Bloomberg School of Public Health Setting Up a Smoking Cessation Clinic Sophia Chan PhD, MPH, RN, RSCN Department of Nursing Studies.
Prepared by J. Mabbutt & C. Maynard NaMO September : Pharmacotherapies – Pain Management.
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
End Simplify A. 13B. 147 C. 17D – 2(5)+7.
TRANSITIONING FROM PP EXTRACT TO A VENDOR NEUTRAL DATA EXTRACTION APPROACH RUTH JENKINS, PHD AUGUST 22, 2014 ©PPRNET 2014.
Ann M. Manzardo, Ph.D. Department of Psychiatry & Behavioral Sciences Kansas University Medical Center Kansas City, Kansas © AMSP 1.
Pharmacologic Treatment Options for Alcohol Dependency Damon Landreau, D.O. LCDR/USPH/USCG Flight Surgeon.
Evidence-Based Guidelines for Pharmacotherapy in Alcohol Dependence Chandan Nayak, MD Addiction Fellow University of Michigan Department of Psychiatry.
Styles of communication Used with permission, University of Florida, Psychiatry Dept.
Drugs used in the Treatment of Alcohol Abuse/Addiction Tristan Knowles.
Vaccination For Treatment of Cocaine Dependence Thomas A. Nguyen, M.D. University of Cincinnati, College of Medicine 1 © AMSP 2011.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health.
Pharmacogenetics of Alcohol Use Disorders Joseph P. Schacht, Ph.D. Department of Psychiatry & Behavioral Sciences Medical University of South Carolina.
Bipolar Disorder and Alcohol Use Disorders Marcy Verduin, M.D. University of Central Florida 1 © AMSP 2010.
Chapter 15 NATURE AND NURTURE. You Started as One Cell: Stem cells.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
A Brief Office Intervention for Alcohol Abuse F. David Schneider, MD, MSPH University of Texas Health Science Center at San Antonio.
Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Prevalence of Alcohol Use Disorders
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Medication Assisted Treatment for Alcohol and Opioid Dependence Larissa Mooney, M.D. Assistant Professor of Psychiatry UCLA Integrated Substance Abuse.
Contemporary Treatments in the Field of Alcohol Misuse Dr Farrukh Alam Consultant Psychiatrist Director of Addictions.
Truman Medical Center Behavioral Health Evidence Based Practices Integrated Dual Disorder Treatment (IDDT)
From screening into treatment: Implementation solutions for Alcoholism therapy Thomas R. Kosten MD JH Waggoner Chair and Professor of Psychiatry & Neuroscience.
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
Sedatives: Anxiolytics & Alcohol
Medical and Specialist Interventions in Alcohol Dependence Peter Rice, Consultant Psychiatrist, NHS Tayside.
Recent Developments in the Pharmacotherapy of Alcoholism Henry R. Kranzler, M.D. Alcohol Research Center Univ. of CT School of Medicine.
Evidence Based Medicine Pharmacological Treatment of Alcohol Dependence.
Pharmacotherapy ofAlcohol Use Disorders in 2015: What is the First Line Medication? David Kan, M.D. Private Practice, UCSF Dept. of Psychiatry (925)
Pharmacotherapy for Alcohol Dependence
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
UCLA Brain Institute Outreach Adrina Kocharian and Rachel Oseas.
Samantha Mohammad And Jack Utz
Medication Assisted Treatment Adding a new medication into outpatient treatment.
Brief interventions. Script I just ask if they are aware of how many units of alcohol they are drinking and that it might be at levels that are.
Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland,
Vivitrol (Naltrexone) Treatment for opioid addiction.
After the ED Alcohol & Drug Treatment Options Dr Mark Daglish Director of Addiction Psychiatry Royal Brisbane & Women’s Hospital.
1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Targeted medication 은 가능한가 ? 알코올 사용장애 환자의 치료 전략으로 건양대학병원 정신과 기 선 완.
The Yale Brief Negotiated Interview Manual (2005) D`Onofrio, Pantalon, Degutis, Fiellin, O’Connor. Yale University.
Specialist service provision. Who is involved in specialist services? Statutory services –Run by NHS and Social Care, these deliver medical and psychosocial.
Michael Fishman, MD Director of Young Adult Program Talbott Recovery Challenges Facing CRC’s and Young Adults in Recovery.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
Identification and Treatment of Alcohol Use Disorders in Primary Care Valerie Carrejo, MD Resident school 8/31/2016.
screening, brief intervention, and referral to treatment
Pegvisomant(DB00082) Approved Drug
Pazopanib: the role in the treatment of mRCC
Identification and Treatment of Alcohol Use Disorders in Primary Care
Opioid Medication Assisted Tx (1)
IV III II I Severe: 5% Harmful: 8%
Chapter 38 Drug Abuse II: Alcohol 1.
Talking to Patients About HCV Treatment
Medication Assisted Treatment for Substance Use Disorders
Medication assisted treatment
Alcoholism and unhealthy use
North Yorkshire Horizons
Identification and Treatment of Alcohol Use Disorders in Primary Care
Pharmacologic Interventions for Unhealthy Drinking
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
Medications used in Treatment of Alcohol and Drug Use Disorders
Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment,
Hazard ratios for associations between incident hepatitis C virus infection and prescribed dosage of opioid agonist treatment, categorized according to.
Presentation transcript:

Styles of communication

University of Florida, Psychiatry Dept.

Styles of communication Rollnick, et al., 2008

Styles of communication

Brief interventions

Steps of the brief intervention D`Onofrio, et al., 2005

Steps of the brief intervention

Steps of the brief intervention

Clinic tools

Practice

Brief intervention ServicePayerCodeDescription Medicaid & Commercial minutes spent administrating and interpreting a full screen, plus performing a brief intervention. MedicareG0396 Medicaid & Commercial Same as above, only 30 minutes. MedicareG0397

ServicePayerCodeDescription Medicaid & Commercial Plus V79.1 or V82.9 Administration and interpretation of a full screen. Medicaid & Commercial minutes spent administrating and interpreting a full screen, plus performing a brief intervention. MedicareG0396 Medicaid & Commercial Same as above, only 30 minutes. MedicareG0397

Referring your patient

Billing

Stages of change Cell phone use increases cancer risk International Agency for Research on Caner (IARC)

Pre- contemplation Contemplation Preparation Action Maintenance Relapse Stages of change

Pre- contemplation Stages of change

Contemplation Stages of change

Preparation Stages of change

Action Stages of change

Maintenance Stages of change

Medications

Naltrexone (Revia) Injectable Naltrexone (Vivitrol) Acamprosate (Campral) Disulfiram (Antabuse) Action Blocks opioid receptors. Thought to interfere with reward pathways important in alcohol dependence. Same as oral naltrexone; 30-day duration Affects glutamate and GABA and neurotransmitter systems but its alcohol- related action is unclear. Inhibits intermediate metabolism of alcohol, causing a buildup of acetaldehyde and reactions if a patient drinks alcohol. Dosage 50 mg QD380 mg IM monthly333 mg tabs, 2 tabs TID250 QD or 500 3X/wk Benefits Modest reductions in relapse rates and severity Side effects Nausea (10%) LFT elevations (uncom.) Nausea (~10%) LFT elevations and sterile abscess (uncom.) Diarrhea (16% vs. 10% in placebo) Liver problems including (rare) fulminant hepatitis Cost $4/day$25/day$4/day Medications

III II IV Making recommendations

III II IV Making recommendations Low risk or abstention

Making recommendations

Practice

Pipeline